Related Experiment Videos
[Anti cancer effect of antibiotic-AFP-purified antibody conjugates]
Abstract:
Antibiotics having antitumor activity (anticancer drugs) also possess inevitable side effects on normal proliferating cells. In order to overcome these side effects, targeting chemotherapy has been developed using antibodies to specific tumor-associated antigens. In this experiment, polyclonal or monoclonal antibodies to AFP (aAFP) were selected for coupling to anticancer drugs such as daunomycin and adriamycin. Dextran (M.W. 10,000) was used as an intermediate drug carrier to increase the number of drug molecules bound indirectly to aAFP. This aAFP-dextran-anticancer drug conjugate produced a striking effect on AFP-producing tumor cells in vivo as well as in vitro using both rat AFP-producing hepatoma AH66 and human ovarian tumor growing in nude mice. The aAFP-dextran-adriamycin conjugate was administered to patients with hepatoma. Although the effect of the conjugate was unclear, long-term suppression of serum AFP level was observed in one case. No obvious side effect encountered.
Insights
Targeted chemotherapy using antibodies against alpha-fetoprotein (AFP) linked to anticancer drugs showed effectiveness against AFP-producing tumors. This novel approach minimized side effects in preclinical models and showed potential in a patient with hepatoma.
Area of Science:
- Oncology
- Immunotherapy
- Drug Delivery Systems
Background:
- Conventional anticancer drugs cause side effects on normal proliferating cells.
- Targeted chemotherapy utilizes antibodies against tumor-associated antigens to deliver drugs specifically to cancer cells.
Purpose of the Study:
- To develop a targeted drug delivery system using antibodies against alpha-fetoprotein (aAFP) conjugated to anticancer drugs.
- To evaluate the efficacy and safety of this conjugate in preclinical models and a human hepatoma patient.
Main Methods:
- Antibodies to alpha-fetoprotein (aAFP) were coupled to anticancer drugs (daunomycin, adriamycin) using dextran as an intermediate carrier.
- The aAFP-dextran-anticancer drug conjugate was tested in vitro and in vivo on AFP-producing hepatoma cells and human ovarian tumors.
- The aAFP-dextran-adriamycin conjugate was administered to patients with hepatoma.
Main Results:
- The aAFP-dextran-anticancer drug conjugate demonstrated significant efficacy against AFP-producing tumor cells in both in vitro and in vivo models.
- In a hepatoma patient, administration of the aAFP-dextran-adriamycin conjugate led to long-term suppression of serum AFP levels.
- No significant side effects were observed with the conjugate treatment.
Conclusions:
- Antibody-drug conjugates targeting alpha-fetoprotein represent a promising strategy for cancer therapy.
- This targeted approach offers potential for reduced toxicity and improved therapeutic outcomes in AFP-producing tumors.